Table 1.
Baseline of included studies.
| No. | Name | Year | Country | Number | Age | Age at diagnosis of AGM | Indicators | Quality | Serum ferritin |
|---|---|---|---|---|---|---|---|---|---|
| 1 | El-Hazmi MA | 1994 | Arabia | 50 | <15 | NR | DM, IGT | 5 | NR |
| 2 | Group IW | 1995 | Italy | 1861 | 1-40 | NR | DM, EnD | 5 | NR |
| 3 | Jensen CE | 1997 | UK | 97 | NR | NR | EnD | 5 | NR |
| 4 | Arrigo T | 1998 | Italy | 29 | 17-42 | NR | DM | 5 | NR |
| 5 | Borgna-Pignatti C | 1998 | Italy | 1146 | NR | NR | DM | 5 | NR |
| 6 | Theodoridis C | 1998 | Greece | 143 | 7-29 | NR | EnD | 4 | NR |
| 7 | Labropoulou-Karatza C | 1999 | Greece | 44 | 16-68(26.8±9) | NR | DM | 5 | 2819±2450 ng/mL |
| 8 | Cario H | 2000 | Germany | 157 | 1-37.5 | NR | IGT | 4 | NR |
| 9 | Chern JP | 2001 | Taiwan, China | 82 | 14.8±6.9 | 17.4(7-24) | IGT | 4 | 3701.3±2530.7 ug/L |
| 10 | Li CK | 2002 | HK, China | 232 | 1.4-30.3 | NR | DM | 5 | 5140(468-48490 pmoL/L) |
| 11 | Borgna-Pignatti C | 2004 | Italy | 720 | NR | 7m(1d-3y) | DM | 5 | NR |
| 12 | Kattamis C | 2004 | Greece | 263 | 11-14 | NR | DM, IGT | 5 | NR |
| 13 | De Sanctis V | 2004 | Italy | 3817 | NR | NR | DM, EnD, IFG | 5 | NR |
| 14 | Khalifa AS | 2004 | Egypt | 48 | 10-31(15.9±5.7) | 16.8±4.5(11-23) | DM, IGT | 5 | 3648±2219 ug/L |
| 15 | Mowla A | 2004 | Iran | 98 | 8-32(15.9±4) | NR | DM | 5 | NR |
| 16 | Fung EB | 2006 | USA | 141 | 25.8±8.1 | NR | DM | 5 | 3601±2351 ug/L |
| 17 | Suvarna J | 2006 | India | 30 | 8-15 | NR | DM | 5 | 7623±2381 ng/mL |
| 18 | Mehrvar A | 2008 | Iran | 437 | 34.7±1.4 | NR | DM | 4 | NR |
| 19 | Jaruratanasirikul S | 2008 | Thailand | 48 | 13.6±3.9 | 11-16 | DM, IGT | 4 | 5206±3291 ug/L |
| 20 | Kidson-Gerber GL | 2008 | Australia | 44 | over 18 | NR | DM | 4 | NR |
| 21 | Gamberini MR | 2008 | Italy | 273 | 13.9±1.4 | NR | DM | 5 | NR |
| 22 | Mula-Abed WA | 2008 | Oman | 30 | 16-32(21.23±3.42) | 17.6±2.1(15-21) | DM, EnD | 5 | 5647±3363 ug/L |
| 23 | Najafipour F | 2008 | Iran | 56 | 15.62±4.44 | 19.8±4.3 | DM, IGT, IFG | 5 | 2888±948 ug/dL |
| 24 | Thuret I | 2010 | France | 215 | 0.6-61.2 | NR | DM | 5 | 1240(89-7893) ng/mL |
| 25 | Farmaki K | 2011 | Greece | 15 | 20-45(35±4.5) | NR | IGT, EnD | 4 | NR |
| 26 | Bazrgar M | 2011 | Iran | 555 | 13.8±5.4 | NR | DM | 5 | NR |
| 27 | Lobo C | 2011 | Brazil | 960 | 28.5±19.8 | NR | EnD | 5 | 2000(405-15874) mcg/L |
| 28 | Kurtoglu AU | 2012 | Turkey | 70 | 18.66±6.48 | NR | DM, IGT | 5 | 2350±450 ng/mL |
| 29 | Belhoul KM | 2013 | Arab | 382 | 15.4±7.6 | 18±3.7 | DM, EnD | 5 | 2597.2±1976.8 ng/L |
| 30 | Mokhtar GM | 2013 | Egypt | 447 | 0.9-35(14.2±7.7) | NR | EnD | 5 | 1817±1399 ng/mL |
| 31 | Canatan D | 2013 | Turkey | 246 | 15.3±8.6 | NR | DM | 5 | 4297.2±2122.5 ng/mL |
| 32 | Mohseni F | 2014 | Iran | 30 | 5-19(14±4.4) | NR | IFG | 5 | NR |
| 33 | Casale M | 2014 | Italy | 86 | 5-49(23.06±12.6) | NR | DM | 5 | NR |
| 34 | Gozashti MH | 2014 | Iran | 300 | NR | NR | EnD | 5 | NR |
| 35 | Metwalley KA | 2014 | Egypt | 60 | 6-18 | 15.6±1.2 | DM, IGT | 5 | 3011±2101 mg/L |
| 36 | Chen YG | 2015 | Taiwan, China | 1537 | 38.2±14.1 | NR | DM | 5 | NR |
| 37 | Al-Akhras A | 2016 | Egypt | 100 | 12-18(14.2±1.37) | NR | DM | 5 | 3577.5±1826 mg/L |
| 38 | Sharma R | 2016 | India | 89 | 13.6±2.5 | NR | DM, EnD, IFG | 5 | 6667±3294 pmoL/L |
| 39 | Altincik A | 2016 | Egypt | 45 | 12-18(14.2±1.37) | NR | DM, IGT, IFG | 5 | NR |
| 40 | Mashhadi MA | 2017 | Iran | 163 | 17.80±5.27 | NR | DM | 5 | 4563.50±2849.30 ng/mL |
| 41 | Liang Y | 2017 | China | 267 | 7.9±0.2 | NR | DM, IFG | 5 | 4476±158 ug/L |
| 42 | Wu HP | 2017 | Taiwan, China | 454 | 0.1-48 | NR | DM | 5 | NR |
| 43 | Gomber S | 2018 | India | 67 | 7.43±4.48 | NR | DM, IGT, IFG | 5 | NR |
| 44 | Teawtrakul N | 2018 | Thailand | 91 | 19.5±10 | NR | DM | 5 | NR |
NR: not reported; DM: diabetes mellitus; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; AGM: abnormal glucose metabolism.